09:59 AM EDT, 09/03/2025 (MT Newswires) -- Genmab ( GMAB ) said Wednesday that updated results from its phase 2 trial of epcoritamab in adults with relapsed and refractory diffuse large B-cell lymphoma demonstrated the feasibility of treating and monitoring patients in an outpatient setting after the first dose.

The study also showed that epcoritamab's adverse event profile and efficacy were consistent with previous studies, the company said.

Shares of Genmab ( GMAB ) were up more than 3% in recent Wednesday trading.

Price: 26.74, Change: +0.85, Percent Change: +3.29